Toremifene

[John Juan]

***Click the SuperiorPeptide banner in my signature for (Toremifene) in the Research Liquids section***

Toremifene: Usually dosed around 60 mgs, some dose it up to 240 mgs. Its androgenicity:estrogenicity ratio is 5x that of Nolvadex. It is prescribed to female patients for breast cancer and has shown a high affinity for bonding to the Estrogen receptors in the breast tissue. Male patients treated with toremifene citrate 80 mg compared to placebo demonstrated statistically significant increases in bone mineral density in the lumbar spine, hip, and femur skeletal sites. It decreased the risk by up to 50%. Toremifene citrate 80 mg treatment compared to placebo also resulted in a decrease in total cholesterol, LDL, and triglycerides, and an increase in HDL. There were also statistically significant improvements in gynecomastia. This data are from an ongoing study of men receiving treatment for ADT (androgen depravation therapy). These men are receiving ADT for advanced prostate cancer. ADT removes much of the testosterone and estrogen in the body which helps the prostatic cancer cells grow. So these men were suffering from side effects from reduced estrogen and testosterone in the body. Some studies have even suggested that Torm doesn't regulate progesterone receptors and we may see in the future the possibility of using it with 19-nors.

 

[Kevlor]

What you like best? Toremifene or clomiphene?

 

[ibleedoranbla]

Is this a better option than nolvadex?

 

[John Juan]

My research rat responds real well to Clomid. It gives him a sense of well being, and incredible muscle strength and hardness. He hasn't sampled Toremifene yet.

 

[John Juan]

The beneficial effects of toremifene administration on the hypothalamic-pituitary-testicular axis and sperm parameters in men with idiopathic oligozoospermia.

AuthorsFarmakiotis D, et al. Show all Journal
Fertil Steril. 2007 Oct;88(4):847-53. Epub 2007 Apr 6.

Affiliation
Abstract
OBJECTIVE: To evaluate whether toremifene, a selective estrogen receptor modulator (SERM), has a beneficiary effect on all three main sperm parameters.

DESIGN: Prospective interventional clinical study.

SETTING: University hospital.

PATIENT(S): One-hundred subfertile men with idiopathic oligozospermia.

INTERVENTION(S): Toremifene (60 mg daily) was administered to all men for 3 months. At baseline and at the end of each month, serum concentrations of follicle-stimulating hormone (FSH), testosterone, inhibin B, and sex hormone-binding globulin (SHBG) were measured. At baseline and at the end, semen analysis was performed and sperm concentration, spermatozoal motility and normal sperm forms were determined.

MAIN OUTCOME MEASURE(S): Gonadotropin, testosterone, inhibin-B levels, total sperm count, sperm morphology and motility.

RESULT(S): Toremifene administration resulted in a significant increase in FSH, testosterone, SHBG, and inhibin B levels, as well as in sperm concentration, percentage motility and normal sperm forms. Twenty-two men's partners achieved pregnancy within 2 months of the end of treatment. At the end of the third month, serum FSH levels were significantly higher in the men whose partners did not achieve pregnancy, and total sperm count and normal sperm forms were significantly lower compared with the group of men whose partners achieved pregnancy.

CONCLUSION(S): Toremifene administration for a period of 3 months in men with idiopathic oligozoospermia is associated with significant improvements of sperm count, motility, and morphology, mediated by increased gonadotropin secretion and possibly a direct beneficial effect of toremifene on the testes. The above findings are also indicative of a better testicular exocrine (improved sperm parameters) response to treatment in men whose partners achieved pregnancy compared with those who did not. Further randomized, placebo-controlled trials should be conducted to determine whether this particular selective estrogen receptor modulator can be useful as an initial approach in men with oligozoospermia.

PMID 17412336 [PubMed - indexed for MEDLINE]
Full text: Elsevier Science

 

[John Juan]

Great for pct.

 

[SMW235]

Clomid better for hpta reboot than torem.

Torem better for hpta reboot than nolva.

Nolva is better for gyno than torem and clomid.

Ralox is the best of all for gyno.

I've used them all and that's my opinion on it only.

 

[John Juan]

Clomid better for hpta reboot than torem.

Torem better for hpta reboot than nolva.

Nolva is better for gyno than torem and clomid.

Ralox is the best of all for gyno.

I've used them all and that's my opinion on it only.

They need to make one compound that's the best of each mentioned.

 

[SMW235]

No kidding.

My cabinet looks like a drug store.

All in 1 would be great.

 

[John Juan]

No kidding.

My cabinet looks like a drug store.

All in 1 would be great.

Do you think Toremifene would keep your test production up best while on cycle?